Company / R&D Expense
Bio-Rad Laboratories R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$275.6M
FY2025
5-year range
$247.4M / $295.9M
FY2021-FY2025
Trend
-6.9%
vs FY2024
Sector context
#27 of 110
Health Care
What the data says
Bio-Rad Laboratories's r&d expense of $276M is higher than 75% of companies in the Health Care sector (FY2025). R&D Expense has fluctuated over the past 10 years, ranging from $193M in FY2017 to $296M in FY2024.
Based on SEC 10-K filings.
$276M in FY2025 with a 5-year CAGR of +6.7%. Top quartile in the Health Care sector.
Improved from $247M to $276M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +2.4%
- 5-Year CAGR
- +6.7%
- 10-Year CAGR
- -
Sector benchmark
Top 25% in Health CareTop 25% of 110This company $275.6M Sector average $298.2M
▼
-7.6% below sector average
Key checks
Key Insights
- 5-year CAGR of +6.7%, indicating consistent growth.
- In FY2025, r&d expense decreased 6.9% year-over-year.
- Ranks #27 out of 110 companies in the Health Care sector.
- Peak r&d expense was recorded in FY2024.
Company context
Key Data Points
- Strong return on equity: 23.0%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $275.6M | -6.9% |
| FY2024 | $295.9M | +19.6% |
| FY2023 | $247.4M | -3.7% |
| FY2022 | $256.9M | -1.4% |
| FY2021 | $260.6M | +30.8% |
| FY2020 | $199.2M | -1.7% |
| FY2019 | $202.7M | -1.5% |
| FY2018 | $205.7M | +6.6% |
| FY2017 | $193.0M | -12.4% |
| FY2016 | $220.3M | +14.2% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026